Hemab co-founder to start over in cancer company
Johan Faber is exiting the company that he co-founded to bring a new company, Ebumab, to similar heights. ”Looking into the future, this is the right decision for me and both companies,” he says.
by albert rønning-andersson, translated by daniel pedersen
Biotech company Hemab, which recently raised USD 135m in Series B financing, is bidding its co-founder and chief technology officer, Johan Faber, farewell. Faber has been tapped for the CEO role at cancer company Ebumab.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Hemab raises USD 135m in Series B financing
For subscribers
Hemab tight-lipped on deals with Novo Nordisk and Genmab
For subscribers
.jpg&w=384&q=75)
